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QuantiFERON-TB-GOLD In-Tube in patients with sarcoidosis
Abstract
Introduction: Sarcoidosis and tuberculosis (TB) are the diseases that share many similarities. Mycobacterium tuberculosis (MTB) 
culture results are the gold standard for the diagnosis of TB, but false positive results are not rare. 
The aim was to evaluate the utility of QFT in detecting latent TB infection in a group of sarcoidosis patients with negative history of 
TB and negative culture/BACTEC results, and checking sarcoidosis activity influence on the QFT results. Additionally, we assessed 
if QFT negative result may strengthen the suspicion that positive culture/BACTEC results are false positive.
Material and methods: 37 culture-negative and 6 culture-positive sarcoidosis patients were enrolled. On the basis of clinical 
and radiological data TB was considered unlikely (false-positive results). A control group consisted of age-matched subjects 
with excluded TB (n = 37). QuantiFERON-TB GOLD In-Tube (QIAGEN, USA) was used according to the manual. Test validity was 
checked basing on the results obtained from a low-risk (n = 21) and active TB group (n = 23). 
Results: The frequency of positive results tended to be higher in MTB(–) sarcoidosis (24.3% vs. 13.5% for the control group, 
p = 0.37), but was similar to the general population. None of culture-positive sarcoidosis patients was QFT-positive. The positive 
results were equally distributed among patients with active and inactive sarcoidosis. 
Conclusions: QFT has been found to be the useful test for the detection of latent TB infection in sarcoidosis patients. In addi-
tion, we confirm that sarcoidosis activity does not negatively influence the result of QFT. Moreover, QFT would be proposed as 
a cost-saving diagnostic test providing additional diagnostic information when false positive MTB culture result in the sarcoidosis 
patient is highly suspected. However, in each case clinical, radiological and epidemiological data should be considered before 
taking the therapeutic decision. 
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Introduction
Sarcoidosis and tuberculosis (TB) are the 
diseases that share many similarities respon-
sible for difficulties in differential diagnosis. 
Mycobacterium tuberculosis (MTB) antigens 
have been suspected to induce sarcoidosis [1], 
and the coexistence of both entities seems to be 
possible [2]. The recent molecular studies have 
also revealed that the diseases have similar blood 
transcriptional signature [3, 4]. That is why, intri-
guing hypothesis of sarcoidosis and tuberculosis 
as the two ends of the same disease spectrum has 
been proposed [5].
Clear-cut differential diagnosis may be 
critical in a clinical setting, as misdiagnosis or 
oversight of TB potentially brings serious epi-
demiological threat. The gold standard for TB 
recognition is the positive culture result for MTB, 
however, negative sputum results do not exclude 
the disease. Moreover, false positive results are 
not infrequent, and have been reported even in 
reference laboratories [6]. 
The tuberculin skin test (TST) — negative in 
almost all sarcoidosis patients due to the periphe-
ral anergy — is not a valuable tool for detecting 
latent TB infection in these patients, however, 
positive results in active sarcoidosis strongly 
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suggest coexistent TB [7]. In vitro IFN-gamma re-
lease assays (IGRAs), which have been developed 
in the last decade, are considered most accurate 
for detection of latent TB infection (LTBI) [8]. An 
alternative to TST, but with higher specificity 
and sensitivity, these tests identify individuals 
infected with MTB, and are of great importance 
in BCG-vaccinated population, like the Polish 
one. Upon the stimulation with mixture of anti-
gens: early secretory antigenic target 6 (ESAT-6), 
culture filtrate protein 10 (CFP-10) and TB7.7, 
QuantiFERON-TB Gold In-Tube test measures 
IFN-gamma concentration by the use of ELISA. It 
is of note however, that this commercial test does 
not discriminate between patients with LTBI and 
those with active disease [9, 10]. 
The results of already published studies into 
the use of IGRA tests in the diagnosis of latent 
TB infection in sarcoidosis patients are not fully 
conclusive [11–13]. Although the authors are 
concordant as to the fact that positive results are 
not more frequent than in non-sarcoidosis control 
subjects, none of these studies provided data on 
sarcoidosis patients with suspected coexistent tu-
berculosis on the basis of positive culture results. 
Besides, data on the influence of the activity of 
sarcoidosis and consequent peripheral depletion 
of T cells on the final result of IGRA test are also 
scarce. 
Therefore, questions to be addressed in the 
present study are the following: 1) What is the 
utility of QFT in detecting latent TB infection in 
a group of sarcoidosis patients with negative hi-
story of TB and negative culture/BACTEC results? 
2) Does sarcoidosis activity influence the QFT 
results? 3) Can QFT negative result strengthen the 
suspicion that positive culture/BACTEC results 
are false positive?
Material and methods
Study groups
Sarcoidosis — The MTB true negative
Consecutive 37 patients admitted to the De-
partment for the confirmation of sarcoidosis, and 
in whom the diagnosis was confirmed according 
to international guidelines [14] were included. 
In all patients, diagnostic bronchoscopy did 
not reveal MTB, neither in smear nor in cultu-
re examination. The previous treatment of TB 
or contact with a person known to have active 
infection were the exclusion criteria. This was 
assessed by a dedicated self-prepared question-
naire, and negative answers were required to all 
the questions below: Have you ever been told by 
a doctor to have TB? Have you ever been treated 
for TB? Have you ever been suspected of TB? Have 
you ever had any contacts with someone known 
to suffer from TB? This subgroup will be further 
indicated as SarcMTB(-) group. See table 1 for details 
of demographic and clinical data.
Sarcoidosis — The MTB false positive
An additional group consisted of six pa-
tients with the primary diagnosis of sarcoidosis 
(criteria as above), in whom MTB was isolated 
incidentally (BACTEC or culture of bronchial 
sample) during routine diagnostic bronchoscopy 
performed at the beginning of diagnostic route of 
sarcoidosis. Examination of bronchial washings 
for the presence of MTB is a routine practice in 
patients suspected of sarcoidosis, but in all these 
subjects the positive result was an unexpected 
finding. The follow-up observation and clinical 
data confirmed false negative MTB culture/ 
/BACTEC results. All these patients were smear-
negative, and in all of them, the second sample 
was smear- and culture-negative. Historical TST 
was also negative in all individuals. All had nega-
tive history of TB and denied a contact with any 
subject suffering from active TB. This subgroup 
will be further indicated as SMTB(false+). TB in these 
patients was considered highly improbable, ma-
inly due to inconsistent clinical (patients 2,4,5 
with acute onset sarcoidosis), and radiological 
presentations (patients 1,2,4,5 with no signs of 
parenchymal involvement, only enlarged hilar 
bilateral lymph nodes). A follow-up evaluation 
also revealed inconsistent reaction to anti-TB 
treatment (progression despite treatment in 
patients 3 and 6) or to the absence of treatment 
(full recovery in patients 1 and 4, despite lack 
of anti-TB treatment). Four patients were treated 
with anti-TB drugs (isoniazid 5 mg/kg, rifampicin 
10 mg/kg (no more than 0.6 g/day), pyrazinamide 
25 mg/kg and ethambutol 15 mg/kg): patients 
3 and 6 due to progressive parenchymal changes 
associated with positive culture results and the 
patient 5 with very low probability of TB infec-
tion but due to high potential epidemiological 
threat (primary school teacher), and in the patient 
2 also with very low TB probability, the decision 
was made by a pulmonologist from another insti-
tution. In four patients, oral prednisone (initially 
0.5 mg/kg) was introduced after the diagnosis of 
sarcoidosis had been established (patients 1, 2, 
3 and 6), but before blood sample for QFT was 
taken. The demographic and clinical data are pro-
vided in Table 1, and the detailed characteristics 
of SMTB(false+) patients in Table 2. 
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Table 1.  Characteristics of the study group consisted of sarcoidosis patients with negative culture/BACTEC results 
(SarcMTB(–) group) and sarcoidosis with positive culture/BACTEC results (SarcMTB(false+) group)
Group Age (years)
mean (SD)
Gender Initial
X-ray stage
LS
at onset
Active disease 
at V(0)
SarcMTB(–) 
(n = 37)
44 (11) F — 13 (35%)
M — 24 (65%)
I — 16 (43%)
II — 20 (54%)
III — 1 (3%)
IV — 0 (0%)
12 (32%) 30 (81%)
SarcMTB(false+) 
(n = 6)
44 (4.7) F — 2 (33%)
M — 4 (67%)
I — 4 (67%)
II — 2 (33%)
3 (50%) 2 (33%)
F: female; LS: Löfgren syndrome; M: male; MTB: mycobacterium tuberculosis; S: sarcoidosis; SD: standard deviation
Table 2.  Detailed characteristics of sarcoidosis patients with positive culture or BACTEC results from bronchoscopy 
sample (SarcMTB(+) group)
Patient Gender Age X-ray stage
at onset
LS at 
onset
Extra- 
-pulmonary
sarcoidosis
Method of 
MTB  
assessment
Sarcoidosis
activity
at V(0)
Anti-TB  
treatment
Follow-up
1 M 45 I No Eyes BACTEC Inactive No Recovery
2 M 37 I Yes No BACTEC Inactive Yes Recovery
3 F 41 II No No Culture
3 colonies
Active Yes Chronic pro-
gressive
4 M 47 I Yes No BACTEC Inactive No Recovery
5 F 48 I Yes No Culture
2 colonies
Inactive Yes Recovery
6 M 47 II No No Culture
2 colonies
Active Yes Chronic  
progressive
In patients 2, 3, 5, 6 the decision of anti-TB treatment was made in a consequence of the positive culture or BACTEC result obtained during diagnostic procedures of 
suspected sarcoidosis. Radiological changes recovered completely in patients 1 and 4 without anti-TB treatment. In patients 3 and 6 radiological changes progressed 
despite anti TB-treatment; F: female; M: male; TB: tuberculosis
The control group 
The control group (n = 37, 17 females) — 
consisted of inhabitants of Lodz city and Lodz 
province. The group was composed of healthy 
volunteers, age-matched to the sarcoidosis group. 
All subjects completed the questionnaire con-
cerning individual TB history, and the answers 
to all questions were negative. In all patients, 
chest X-ray was normal, or in case of abnormal 
chest x-ray, tuberculosis could be unambiguously 
excluded. None of these patients were treated 
with systemic steroids or immunosuppressive 
drugs, nor suffered any disease connected with 
depleted immune response. None of the subjects 
had a positive history of sarcoidosis.
The TB low- risk group
Medical students (n = 21, 6 females) with no 
history of TB or TB contacts, as assessed by a TB 
questionnaire. Chest X-ray taken during the last 
12 months was normal. 
The active TB group 
Patients (n = 23, 9 females) actually treated 
due to lung tuberculosis (between 2nd and 6th week 
of treatment), with typical clinical and radiolo-
gical picture and positive sputum or bronchial 
washing culture results.
Sarcoidosis patients were followed up for at 
least 2 years (regular every 3–6-month visits in 
out-patient department and telephone check-ups).
All subjects participating in the study were 
provided with relevant information, after which 
they signed the consent. The Ethical Committee at 
Medical University of Lodz approved the protocol 
(RNN/110/14/KE).
QuantiFERON-TB GOLD In-tube (QFT) was 
performed according to the manufacturer’s  in-
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Table 3. Results of QuantiFERON TB GOLD test in all subgroups — Fisher’s exact test
Group Positive Negative All % Versus control group
(p-value)
Versus low TB risk group
(p-value)
SarcMTB(false+) 0 6 6 0 1.0 1.0
SarcMTB(-) 9 28 37 24.3 0.37 0.08
Sarc (entire) 9 34 43 20.9 0.56 0.15
Control 5 32 37 13.5 – 0.4
TB active 16 7 23 69.6 – < 0.00001
Low TB risk 1 20 21 4.8 – –
struction (QIAGEN, Germany). Briefly, 5 ml of blo-
od was withdrawn from a cubital vein into three 
collecting tubes (Nil tube, MTB tube, mitogen 
tube). Samples were incubated and centrifuged. 
Afterwards plasma was collected and frozen in 
–20oC until measurements. After defrosting, the 
samples were transferred onto 96-wells plate and 
tested for the presence of interferon gamma (IFN-g) 
by ELISA method. Optical density (OD) of each 
well was measured using multiplate reader BioTek 
ELx 800 equipped with a 450-nm filter (620 nm 
for reference). OD values were taken to calculate 
the results, according to standard curve drawn 
basing on provided standards. The results were 
interpreted as positive, negative or indeterminate.
Frequencies of positive and negative outco-
mes were calculated for sarcoidosis with negative 
TB results, positive TB results, and for entire sar-
coidosis group. These values were compared with 
those of dedicated control group and of low-TB 
risk group, using the Fisher’s exact test.
Results
The incidence of positive QFT results 
among sarcoidosis patients with negative cul-
ture/BACTEC results for MTB (SarcMTB(–)) was 
slightly higher than in the control group of 
age-matched non-sarcoid subjects, however, the 
difference did not reach the level of statistical 
significance (p = 0.37). None of the sarcoidosis 
patients with positive culture/BACTEC results 
for MTB (SarcMTB(false+)) had positive QFT result. 
When results of the entire sarcoidosis group 
(SarcMTB(-)and SarcMTB(false+)) were calculated, still 
no differences compared to controls were fo-
und. In fact, the level of significance was even 
lower, due to the decrease of the percentage of 
positive results in the entire sarcoidosis group 
(p = 0.56). Table 3 shows detailed results within 
all study groups.
Discussion
In our outcomes, the frequency of latent tuber-
culosis infection based on QFT results is not signifi-
cantly higher when compared to age-matched con-
trols. Results obtained by other authors are similar: 
low incidence of positive results among Danish 
sarcoidosis patients [11] or high (however, corre-
sponding to high incidence of TB in the studied 
society) frequency of positive results documented 
by authors from India [12]. In the study perfor-
med by other researchers among Polish, formerly 
vaccinated sarcoidosis patients, the percentage of 
positive results was 4.6 when assessed by QFT, 
and 3.7 when assessed by T-SPOT TB test [13]. 
Although the percentage of positive outcomes in 
our sarcoidosis group was slightly higher than in the 
control group, it well matched the 20.4% prevalence 
of latent TB reported for Polish blood donors [15]. 
Therefore, it is justified to say that the frequency of 
latent TB infection in sarcoidosis patients reflects 
the one reported in the general population, from 
which sarcoidosis patients originate. 
By using QFT we were able to show negative 
QFT results in all sarcoidosis patients with highly 
suspected false positive culture results. Tuber-
culosis in these patients was recognized as unli-
kely using similar approach as Fischl et al. [16], 
therefore using clinical outcome, despite an 
initial positive culture for M. tuberculosis. Al-
though such approach would be recognized as 
controversial, careful follow-up justified rightness 
of our decision. We emphasize that QFT negative 
result alone cannot be used as a proof of false-
negative MTB culture, however, in confrontation 
with the overall clinical description, it was reco-
gnized as potentially useful additional diagnostic 
information. To the best of our knowledge, this is 
the first study with the use of QFT in sarcoidosis 
patients, which also included those with positive 
culture results. 
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Among the sarcoidosis group with positive 
culture results, in all patients, the possibility of TB 
infection was considered as very low. Therefore, in 
two of them, the decision to abandon the anti-TB 
treatment was taken. Both patients with stage 
I disease were free of symptoms and their chest 
X-rays were normal at follow-up examination, even 
though one was treated with systemic steroids for 
over 12 months due to ocular sarcoidosis. In the 
remaining two patients with stage I sarcoidosis, the 
anti-TB treatment was introduced (Pt 5, a primary 
school teacher — due to potential high epidemio-
logic threat, and Pt 2, following decision of a pul-
monologist representing another center, and his 
opinion on this matter was not shared by our gro-
up). Systemic steroids were applied in 4 patients. 
In none systemic steroids were introduced prior 
to obtaining the positive culture/BACTEC results.
As the interpretation, two possibilities should 
be considered: the occurrence of false negative 
results of QFT or false positive results of bronchial 
aspirate culture. The pooled analysis of QFT re-
sults from different studies revealed the sensitivity 
of 80% and specificity of 79% [17]. Also, in other 
studies, false negative IGRA results are not rare 
in active TB [18, 19]. At risk are small children 
with severe TB forms, those with reduced number 
and function of lymphocytes [20–22], patients in 
immunosuppression related to different diseases, 
lower platelet, protein and albumin levels, or 
senility [19–22]. None of the study subjects pre-
sented any of the described conditions. Therefore, 
false-negative QFT results may not be excluded 
with full confidence. A second possibility are false 
positive sputum-culture results for MTB. It is not 
surprising, as specimen cross-contamination with 
MTB was reported in many laboratories [6, 23, 24]. 
A cross-contamination of TB strains was studied 
in our city by the use of genotyping methods, and 
was found in 4 out of 98 clustered strains [25]. 
Taking into consideration all clinical, radiological, 
and laboratory results, we are convinced of false 
culture results in all these sarcoidosis patients. 
The most important features in support of this in-
terpretation and present in our patients in variable 
constellations, are: predominance of intrathoracic 
lymph nodes involvement over parenchymal 
disease (isolated lymphonodal tuberculosis may 
happen in primary TB only, therefore it is unlikely 
in adult members of TB vaccinated society), lack 
of endobronchial changes suggestive of TB, acute 
onset, complete resolution of radiological changes 
despite lack of anti-TB treatment, and radiological 
progression regardless of anti-TB treatment. 
Our observations strengthen the suggestion 
that clinicians should not alwaysconfidently re-
peat clichés, but rather evaluate positive cultures 
critically, because such approach would allow to 
decrease the probability of unnecessary treatment 
and its possible complications.
Sarcoidosis is characterized by enhanced 
local immunological reactions and consequent 
peripheral anergy (immunological paradox) [26]. 
T regulatory cells (CD4+CD25+FOXP3+ and 
CD4+CD39+) may be involved, as they in-
completely control the inflammation of injured 
tissues, but are powerful enough to mediate 
peripheral anergy [27, 28]. IGRAs performed 
on whole blood (QFT) or peripheral blood mo-
nonuclear cells (T-SPOT TB) could theoretically 
be negative due to activity of these cells but 
interestingly, it was shown that nTreg cells 
incompletely blocked IFN-gamma and TNF 
secretion by autologous cells [27]. As several 
patients of our group with active disease were 
QFT-positive, the possibility of false negative 
results due to this phenomenon is unlikely. 
It is worth noticing that the new version of 
QFN — QuantiFERON TB Plus accessing in 
addition to CD4+ T-cell response also CD8+ 
T-cell response, which can better discriminate 
active TB from LTBI [29, 30], as well as recent 
exposure to TB [31] will be especially useful in 
situation like ours.
One limitation of our study was a  small 
number of sarcoidosis patients with false-po-
sitive culture results. Another weakness was 
lack of sarcoidosis patients with true concurrent 
TB, which would allow to verify the sensitivity 
and specificity of QFT in this specific clinical 
situation. However, such patients are rare, and it 
seems improbable to recruit satisfactory sample 
of such subjects. 
Conclusion
QFT has been found to be the useful test for 
the detection of latent TB infection in sarcoido-
sis patients. In addition, we confirm that sar-
coidosis activity does not negatively influence 
the result of QFT. Moreover, QFT would be pro-
posed as a cost-saving diagnostic test providing 
additional diagnostic information when false 
positive MTB culture result in the sarcoidosis 
patient is highly suspected. However, in each 
case clinical, radiological and epidemiological 
data should be considered before taking the 
therapeutic decision. 
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